EHA 2024 – Nurix and BeiGene’s degraders shine
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
Merck joins the TIGIT pivotal failure club
Keyvibe-010 fails, but not for the reason you might have expected.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Ascentage’s Venclexta challenge looks wildly optimistic
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
